PT - JOURNAL ARTICLE AU - Filipe Zimmer Dezordi AU - Paola Cristina Resende AU - Felipe Gomes Naveca AU - Valdinete Alves do Nascimento AU - Victor Costa de Souza AU - Anna Carolina Dias Paixão AU - Luciana Appolinario AU - Renata Serrano Lopes AU - Ana Carolina da Fonseca Mendonça AU - Alice Sampaio Barreto da Rocha AU - Taina Moreira Martins Venas AU - Elisa Cavalcante Pereira AU - Richard Steiner Salvato AU - Tatiana Schäffer Gregianini AU - Leticia Garay Martins AU - Felicidade Mota Pereira AU - Darcita Buerger Rovaris AU - Sandra Bianchini Fernandes AU - Rodrigo Ribeiro-Rodrigues AU - Thais Oliveira Costa AU - Joaquim Cesar Sousa, Jr AU - Fabio Miyajima AU - Edson Delatorre AU - Tiago Gräf AU - Gonzalo Bello AU - Marilda Mendonça Siqueira AU - Gabriel da Luz Wallau AU - on behalf of Fiocruz COVID-19 Genomic Surveillance Network TI - Unusual SARS-CoV-2 intra-host diversity reveals lineages superinfection AID - 10.1101/2021.09.18.21263755 DP - 2021 Jan 01 TA - medRxiv PG - 2021.09.18.21263755 4099 - http://medrxiv.org/content/early/2021/09/23/2021.09.18.21263755.short 4100 - http://medrxiv.org/content/early/2021/09/23/2021.09.18.21263755.full AB - The SARS-CoV-2 has infected almost 200 million people worldwide by July 2021 and the pandemic has been characterized by infection waves of viral lineages showing distinct fitness profiles. The simultaneous infection of a single individual by two distinct SARS-CoV-2 lineages provides a window of opportunity for viral recombination and the emergence of new lineages with differential phenotype. Several hundred SARS-CoV-2 lineages are currently well characterized but two main factors have precluded major coinfection/codetection analysis thus far: i) the low diversity of SARS-CoV-2 lineages during the first year of the pandemic which limited the identification of lineage defining mutations necessary to distinguish coinfecting viral lineages; and the ii) limited availability of raw sequencing data where abundance and distribution of intrasample/intrahost variability can be accessed. Here, we have put together a large sequencing dataset from Brazilian samples covering a period of 18 May 2020 to 30 April 2021 and probed it for unexpected patterns of high intrasample/intrahost variability. It enabled us to detect nine cases of SARS-CoV-2 coinfection with well characterized lineage-defining mutations. In addition, we matched these SARS-CoV-2 coinfections with spatio-temporal epidemiological data confirming their plausibility with the co-circulating lineages at the timeframe investigated. These coinfections represent around 0.61% of all samples investigated. Although our data suggests that coinfection with distinct SARS-CoV-2 lineages is a rare phenomenon, it is likely an underestimation and coinfection rates warrants further investigation.DATA SUMMARY The raw fastq data of codetection cases are deposited on gisaid.org and correlated to gisaid codes: EPI_ISL_1068258, EPI_ISL_2491769, EPI_ISL_2491781, EPI_ISL_2645599, EPI_ISL_2661789, EPI_ISL_2661931, EPI_ISL_2677092, EPI_ISL_2777552, EPI_ISL_3869215. Supplementary data are available on https://doi.org/10.6084/m9.figshare.16570602.v1. The workflow code used in this study is publicly available on: https://github.com/dezordi/IAM_SARSCOV2.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFinancial support was provided by FAPEAM (PCTIEmergeSaude/AM call 005/2020 and Rede Genomica de Vigilancia em Saude - REGESAM); Ministerio da Ciencia, Tecnologia, Inovacoes e Comunicacoes/Conselho Nacional de Desenvolvimento Cientifico e Tecnologico - CNPq/Ministerio da Saude - MS/FNDCT/SCTIE/Decit (grants 402457/2020-9 and 403276/2020-9); Inova Fiocruz/Fundacao Oswaldo Cruz (Grants VPPCB-007-FIO-18-2-30 and VPPCB-005- FIO-20-2-87) and INCT-FCx (465259/2014-6). This work was also supported by the Pan American Health Organization, Brazil Country Office. FGN, GLW and GB are supported by the CNPq through their productivity research fellowships (306146/2017-7, 303902/2019, 302317/2017-1, respectively).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Aggeu Magalhaes Institute Ethical Committee - CAAE 32333120.4.0000.5190, FIOCRUZ-IOC Ethics Committee (68118417.6.0000.5248 and CAAE 32333120.4.0000.5190), the Brazilian Ministry of Health SISGEN (A1767C3). Moreover, it was approved by the Ethics Committee of Amazonas State University (no. 25430719.6.0000.5016), which waived signed informed consentAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe raw fastq data of codetection cases are deposited on gisaid.org and correlated to gisaid codes: EPI_ISL_1068258, EPI_ISL_2491769, EPI_ISL_2491781, EPI_ISL_2645599, EPI_ISL_2661789, EPI_ISL_2661931, EPI_ISL_2677092, EPI_ISL_2777552, EPI_ISL_3869215. Supplementary data are available on https://doi.org/10.6084/m9.figshare.16570602.v1. The workflow code used in this study is publicly available on: https://github.com/dezordi/IAM_SARSCOV2. https://doi.org/10.6084/m9.figshare.16570602.v1 https://github.com/dezordi/IAM_SARSCOV2